Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Weide B, Eigentler T, Catania C, Ascierto PA, Cascinu S, Becker JC, Hauschild A, Romanini A, Danielli R, Dummer R, Trefzer U, Elia G, Neri D, Garbe C. Weide B, et al. Among authors: catania c. Cancer Immunol Immunother. 2019 Sep;68(9):1547-1559. doi: 10.1007/s00262-019-02383-z. Epub 2019 Sep 3. Cancer Immunol Immunother. 2019. PMID: 31482307 Free PMC article. Clinical Trial.
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.
Catania C, Maur M, Berardi R, Rocca A, Giacomo AM, Spitaleri G, Masini C, Pierantoni C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, Elia G, Menssen HD, Neri D, Cascinu S, Conte PF, Braud Fd. Catania C, et al. Cell Adh Migr. 2015;9(1-2):14-21. doi: 10.4161/19336918.2014.983785. Cell Adh Migr. 2015. PMID: 25562532 Free PMC article. Clinical Trial.
Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).
Nolè F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G, Martinelli G, Zampino MG, Catania C, Pizzamiglio M, Veronesi P, Zurrida S, Galimberti V, Goldhirsch A, Veronesi U. Nolè F, et al. Among authors: catania c. Ann Oncol. 1999 Aug;10(8):993-6. doi: 10.1023/a:1008389106575. Ann Oncol. 1999. PMID: 10509165 Free article. Clinical Trial.
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
De Pas T, de Braud F, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, del Tacca M, Zampino G, Sbanotto A, Rocca A, Cinieri S, Marrocco E, Milani A, Goldhirsch A. De Pas T, et al. Among authors: catania c. Ann Oncol. 2000 Jul;11(7):821-7. doi: 10.1023/a:1008319923516. Ann Oncol. 2000. PMID: 10997809 Free article. Clinical Trial.
Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
De Pas T, Curigliano G, Masci G, Catania C, Comandone A, Boni C, Tucci A, Pagani O, Marrocco E, de Braud F; Italian Sarcoma Group. De Pas T, et al. Among authors: catania c. Ann Oncol. 2002 Jan;13(1):161-6. doi: 10.1093/annonc/mdf004. Ann Oncol. 2002. PMID: 11863099 Free article. Clinical Trial.
Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study.
De Pas T, Curigliano G, Veronesi G, Catalano G, Catania C, Jereczek-Fossa B, Orecchia R, Spaggiari L, de Braud F. De Pas T, et al. Among authors: catania c. Bull Cancer. 2004 Sep 1;91(9):E273-7. Print 2004 Sep. Bull Cancer. 2004. PMID: 15582897 Free article. Clinical Trial.
155 results